ClinicalTrials.gg
CompletedNCT03020199STEPinUpdated Jan 28, 2025Results posted

Study of the Efficacy of Early Intervention With Secukinumab 300 mg s.c. Compared to Narrow-band UVB in Patients With New-onset Moderate to Severe Plaque Psoriasis

A Phase 4 interventional study of Secukinumab and nb-UVB in Plaque Psoriasis, sponsored by Novartis Pharmaceuticals. Completed at 44 sites in 13 countries. Open to participants aged 18 Years to 50 Years. Per ClinicalTrials.gov, last updated 2025-01-28.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
196
Allocation
Randomized
Ages
18 Years to 50 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 54 studies testing secukinumab in Psoriasis — 5 open to participants now, 5 under way, none of them phase 3. secukinumab · Psoriasis.

Enrollment
20th of 54
196 · median 124
Started
2017
with 4 others
Phase 4
17 of 54
4 open now
Registered
35th of 54
by date
Lead sponsor
37 of 54
Novartis Pharmaceuticals

Among the 54 studies testing secukinumab in Psoriasis, this one is the 20th largest by enrollment, is one of 5 that started in 2017, is one of 17 in phase 4, and was the 35th registered.

Psoriasis

2,030 studies on the registry are indexed under Psoriasis; 276 are open to participants now.

Browse Psoriasis studies →

Open to participants now

5 of the 54 studies testing secukinumab in Psoriasis are open now, in 5 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

About secukinumab

secukinumab: first FDA approval 2015 (COSENTYX), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 173 Psoriasis studies recruiting now, 91 (53%) set no upper age limit and 66 (38%) stop at 75 or younger; 25 take children under 18; 40 take healthy volunteers.

This study: 18 Years to 50 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 54 studies testing secukinumab in Psoriasis, or all of them as a file.
02

Study summary

The purpose of this study was to determine whether early intervention with subcutaneous (s.c.) secukinumab 300 mg in patients with new-onset moderate to severe plaque psoriasis may lead to prolonged symptom-free periods by preventing reactivation of old lesions or ultimately totally hindering the occurrence of new lesions, i.e., changing the natural course of the disease (Main Study).

Read the detailed description

This was and open label, parallel group, multicenter, randomized study with 3 clinical periods: Screening period, Treatment period, and Follow-up period.

The design consisted of the Main Study and a Mechanistic Sub study:

  1. The Main Study had 2-treatment-arm secukinumab and nb-UVB).
  2. The Mechanistic Sub-study had 4 arms treated with secukinumab and one arm with nb-UVB arm. The outcome measures were all exploratory, i.e. no results presented. Not all participants of the Mechanistic Sub-study participated in the Main Study, these participants are only reported for the safety analyses, but not for the primary and secondary outcome measures.
03

Conditions studied

  • Plaque Psoriasis

Browse trials for

Keywords

  • Psoriasis
  • interleukin (IL) 17A
  • IL-17A
  • secukinumab
  • AIN457
  • Narrow-band ultraviolet light B
  • nb-UVB
  • Psoriasis area and severity index
  • PASI
04

Who can participate

Ages eligible
18 Years to 50 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Able to understand and communicate with the investigator, willing and capable to comply with all study procedures, and provide written signed and dated (personally or by a witness) before any assessment is performed.
  • Aged 18 to 50 years inclusive.
  • New-onset plaque psoriasis with appearance of the first psoriasis plaques within the last 12 months before randomization and naïve to any systemic treatment and phototherapy (Arm A1, Arm A2, and Arm B1). Episodes of mild psoriasis, which occurred at least 3 years before screening and resolved spontaneously within 6 months will be accepted.
  • Chronic plaque psoriasis with appearance of the first psoriasis symptoms 5 years or longer and intolerance or inadequate response to phototherapy or any systemic treatment including biologicals, except for IL-17A inhibitors (Arm C1 and Arm C2).
  • Moderate to severe plaque psoriasis defined at screening and baseline by PASI >= 10, and body surface area (BSA) >= 10%, and IGA mod 2011 >= 3.

Key Exclusion Criteria:

  • Forms of psoriasis other than plaque-type (e.g., pustular, erythrodermic, guttate, light sensitive, and drug induced).
  • Ongoing use of prohibited treatments.
  • Previous treatment with phototherapy or any systemic treatment.
  • Pregnant or nursing (lactating) women.
  • Women of , defined as all women physiologically capable of becoming pregnant, unless they are using effective methods of during the Treatment period or longer if required by locally approved prescribing information (e.g., 20 weeks in the EU and countries where applicable for secukinumab).
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
196 participants (actual)

Study arms

  • Experimental
    Secukinumab 300 mg

    In the Main Study, 80 new-onset psoriasis patients in Arm A1 (68 in Arm A1a, 12 in Arm A1b) received 300 mg secukinumab injections weekly for the first month, then every 4 weeks until Week 48 (52-week treatment). Arm A1b patients also joined the Mechanistic Sub-study. In the Mechanistic Sub-study, 12 new-onset psoriasis patients (Arm A2) and 24 chronic plaque psoriasis patients (12 each in Arms C1 and C2) received similar secukinumab treatment. Arm A2 and C2 patients continued until Week 100 (104-week treatment), while Arm C1 ended at Week 48 (52-week treatment).

    Biological: Secukinumab

  • Active comparator
    Narrow-band ultraviolet B (nb-UVB)

    In the Main Study, 80 new-onset psoriasis patients in Arm B1 (68 in Arm B1a and 12 in Arm B1b) received 1 or 2 cycles of nb UVB of 12 weeks each with a maximum break of 28 weeks between cycles (patients with PASI 90 at Week 40 did not receive a second treatment cycle) (treatment duration = 52 weeks). Patients from Arm B1b participated also in the Mechanistic Sub-study.

    Radiation: nb-UVB

Interventions

  • BiologicalSecukinumab

    Secukinumab (AIN457) 300 mg was administered in an open-label fashion according to label as 2 s.c. injections of secukinumab 150 mg (1-mL liquid formulation in a pre-filled syringe). Each 300-mg dose was provided as 2 pre-filled syringes of 150-mg secukinumab in a single box. Each syringe was labeled as AIN457 150 mg/1 mL.

    Also known as: AIN457

  • Radiationnb-UVB

    Narrow-band UVB applied in 1 or 2 cycles, each comprising a period of 12 weeks with 2 to 3 treatment sessions per week totaling 24 to 36 sessions per cycle. The application was performed according to the investigational site's protocol, taking into account the patient's skin type. A maximum dose of 3 J/cm2 on the body and 1 J/cm2 on the face was recommended

06

What researchers measure

Primary outcomes

  1. Number of Participants Who Achieved Pain Assessment Severity Index (PASI) 90 at Week 52.

    The PASI quantifies the severity of a participant's psoriasis based on both "lesion severity" and the "percent of Body Surface Area (BSA)" affected. PASI is a composite scoring by the investigator of degree of erythema, induration, and scaling (each scored separately) for each of 4 body regions (head and neck, upper limbs, trunk \[including axillae and groin\], and lower limbs \[including buttocks\]), with adjustment for the percent of BSA involved for each body region and for the proportion of the body region to the whole body. The PASI composite score varies in increments of 0.1 and range from 0 (no disease) to 72 (maximal disease), with higher scores representing greater severity of psoriasis. PASI 90 response is a binary measure defined as at least a 90% improvement in PASI score at Week 52, relative to baseline PASI score.

    Time frame: Baseline, Week 52

Secondary outcomes

  1. Number of Participants Who Achieved PASI 90 at Week 104

    The PASI quantifies the severity of a participant's psoriasis based on both "lesion severity" and the "percent of Body Surface Area (BSA)" affected. PASI is a composite scoring by the investigator of degree of erythema, induration, and scaling (each scored separately) for each of 4 body regions (head and neck, upper limbs, trunk \[including axillae and groin\], and lower limbs \[including buttocks\]), with adjustment for the percent of BSA involved for each body region and for the proportion of the body region to the whole body. The PASI composite score varies in increments of 0.1 and range from 0 (no disease) to 72 (maximal disease), with higher scores representing greater severity of psoriasis. PASI 90 response is a binary measure defined as at least a 90% improvement in PASI score at Week 104, relative to baseline PASI score.

    Time frame: Baseline, Week 104

  2. Number of Participants With IGA Mod 2011 0/1 Response at Week 52

    Investigators assessed the disease using the validated Investigator Global Assessment (IGA) mod 2011 and rated the disease from a score of 0 (clear skin) to 4 (severe disease). Response is defined as a score of 0 or 1 at Week 52.

    Time frame: Baseline, Week 52

07

Results

Posted Oct 1, 2024

Participant flow

Subjects were enrolled in 2 study sites in Argentina, 4 in Bulgaria, 2 in Canada, 4 in Germany, 1 in Denmark, 3 in Estonia, 2 in Finland, 2 in Hungary, 6 in Poland, 8 in Spain, 2 in Sweden, 1 in Switzerland, and 4 in the United Kingdom.

Treatment Period
Participant flow — Treatment Period
MilestoneSecukinumab 300 mgNarrow-band Ultraviolet B (Nb-UVB)
Started11680
Modified full analysis set (mfas)7776
Subjects not treated34
Main study8080
Mechanistic sub-study360
Completed10346
Not completed1334
Withdrew: Adverse event02
Withdrew: Lack of efficacy16
Withdrew: Lost to follow-up16
Withdrew: Physician decision01
Withdrew: Subject/guardian decision815
Withdrew: Subjects not treated34
Follow-up Period
Participant flow — Follow-up Period
MilestoneSecukinumab 300 mgNarrow-band Ultraviolet B (Nb-UVB)
Started7339
Main study6739
Mechanistic sub-study60
Completed138
Not completed6031
Withdrew: Disease relapse327
Withdrew: Lack of efficacy12
Withdrew: Lost to follow-up46
Withdrew: Physician decision22
Withdrew: Protocol violation12
Withdrew: Study terminated by sponsor63
Withdrew: Subject/guardian decision149

Outcome measures

PrimaryNumber of Participants Who Achieved Pain Assessment Severity Index (PASI) 90 at Week 52.

The PASI quantifies the severity of a participant's psoriasis based on both "lesion severity" and the "percent of Body Surface Area (BSA)" affected. PASI is a composite scoring by the investigator of degree of erythema, induration, and scaling (each scored separately) for each of 4 body regions (head and neck, upper limbs, trunk \[including axillae and groin\], and lower limbs \[including buttocks\]), with adjustment for the percent of BSA involved for each body region and for the proportion of the body region to the whole body. The PASI composite score varies in increments of 0.1 and range from 0 (no disease) to 72 (maximal disease), with higher scores representing greater severity of psoriasis. PASI 90 response is a binary measure defined as at least a 90% improvement in PASI score at Week 52, relative to baseline PASI score.

Time frame:
Baseline, Week 52
Reported as:
Count of participants · Participants
Number of Participants Who Achieved Pain Assessment Severity Index (PASI) 90 at Week 52.
ParticipantsSecukinumab 300 mg A1 (A1a+A1b)Narrow-band Ultraviolet B (Nb-UVB) B1 (B1a+B1b)
Number of Participants Who Achieved Pain Assessment Severity Index (PASI) 90 at Week 52.7032
Statistical analysis
  • Secukinumab 300 mg A1 (A1a+A1b) vs Narrow-band Ultraviolet B (Nb-UVB) B1 (B1a+B1b) · Regression, Logistic · p = <0.0001 · Odds ratio (or): 16.8 · 95% CI 5.9 to 48.3Logistic regression model with treatment as an explanatory variable and subset of significant covariates (including Baseline PASI score, age, BMI and their interaction terms with treatment) selected using forward selection method.
SecondaryNumber of Participants Who Achieved PASI 90 at Week 104

The PASI quantifies the severity of a participant's psoriasis based on both "lesion severity" and the "percent of Body Surface Area (BSA)" affected. PASI is a composite scoring by the investigator of degree of erythema, induration, and scaling (each scored separately) for each of 4 body regions (head and neck, upper limbs, trunk \[including axillae and groin\], and lower limbs \[including buttocks\]), with adjustment for the percent of BSA involved for each body region and for the proportion of the body region to the whole body. The PASI composite score varies in increments of 0.1 and range from 0 (no disease) to 72 (maximal disease), with higher scores representing greater severity of psoriasis. PASI 90 response is a binary measure defined as at least a 90% improvement in PASI score at Week 104, relative to baseline PASI score.

Time frame:
Baseline, Week 104
Reported as:
Count of participants · Participants
Number of Participants Who Achieved PASI 90 at Week 104
ParticipantsSecukinumab 300 mg A1 (A1a+A1b)Narrow-band Ultraviolet B (Nb-UVB) B1 (B1a+B1b)
Number of Participants Who Achieved PASI 90 at Week 1042326
Statistical analysis
  • Secukinumab 300 mg A1 (A1a+A1b) vs Narrow-band Ultraviolet B (Nb-UVB) B1 (B1a+B1b) · Regression, Logistic · p = 0.6530 · Odds ratio (or): 0.8 · 95% CI 0.3 to 2.1Exact logistic regression method for Treatment group comparison, without using any covariates.
SecondaryNumber of Participants With IGA Mod 2011 0/1 Response at Week 52

Investigators assessed the disease using the validated Investigator Global Assessment (IGA) mod 2011 and rated the disease from a score of 0 (clear skin) to 4 (severe disease). Response is defined as a score of 0 or 1 at Week 52.

Time frame:
Baseline, Week 52
Reported as:
Number · Percentage of participants
Number of Participants With IGA Mod 2011 0/1 Response at Week 52
Percentage of participantsSecukinumab 300 mg A1 (A1a+A1b)Narrow-band Ultraviolet B (Nb-UVB) B1 (B1a+B1b)
Number of Participants With IGA Mod 2011 0/1 Response at Week 5285.7 (75.5 to 92.3)36.8 (26.3 to 48.7)

Adverse events

Collected over On-treatment adverse events were collected from first dose of study treatment to 84 days after last dose of study medication (on-treatment), up to approximately 104 weeks. Evaluation of AEs and SAEs were repeated after dosing with study treatment (starting 85 days after last dose of treatment) until study termination notification.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Secukinumab 300 mg - On Treatment0/112 (0%)6/112 (5.4%)29/112 (25.9%)
Narrow-band Ultraviolet B (Nb-UVB) - On Treatment0/76 (0%)1/76 (1.3%)8/76 (10.5%)
Secukinumab 300 mg - Post Treatment Follow-up0/88 (0%)0/88 (0%)7/88 (8%)
Narrow-band Ultraviolet B (Nb-UVB) - Post Treatment Follow-up0/76 (0%)1/76 (1.3%)2/76 (2.6%)
Most frequent serious events
Most frequent serious events
EventSecukinumab 300 mg - On TreatmentNarrow-band Ultraviolet B (Nb-UVB) - On TreatmentSecukinumab 300 mg - Post Treatment Follow-upNarrow-band Ultraviolet B (Nb-UVB) - Post Treatment Follow-up
PancytopeniaBlood and lymphatic system disorders0/1120/760/881/76
Vocal cord polypRespiratory, thoracic and mediastinal disorders0/1121/760/880/76
Umbilical herniaGastrointestinal disorders1/1120/760/880/76
Ankle fractureInjury, poisoning and procedural complications1/1120/760/880/76
Post procedural haemorrhageInjury, poisoning and procedural complications1/1120/760/880/76
Tibia fractureInjury, poisoning and procedural complications1/1120/760/880/76
Acute stress disorderPsychiatric disorders1/1120/760/880/76
AsthmaRespiratory, thoracic and mediastinal disorders1/1120/760/880/76
Most frequent other events
Most frequent other events
EventSecukinumab 300 mg - On TreatmentNarrow-band Ultraviolet B (Nb-UVB) - On TreatmentSecukinumab 300 mg - Post Treatment Follow-upNarrow-band Ultraviolet B (Nb-UVB) - Post Treatment Follow-up
NasopharyngitisInfections and infestations11/1125/763/881/76
HeadacheNervous system disorders11/1121/761/880/76
Upper respiratory tract infectionInfections and infestations8/1122/760/882/76
ArthralgiaMusculoskeletal and connective tissue disorders7/1120/765/881/76

Baseline characteristics

Subject disposition and baseline characteristics and presented using Randomized Set.

Age, Customized
Age, Customized(Participants)Secukinumab 300 mgNarrow-band Ultraviolet B (Nb-UVB)Total
18 to 30 years563086
31 to 50 years6050110
Sex: Female, Male
Sex: Female, Male(Participants)Secukinumab 300 mgNarrow-band Ultraviolet B (Nb-UVB)Total
Female352560
Male8155136
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Secukinumab 300 mgNarrow-band Ultraviolet B (Nb-UVB)Total
Black or African American112
Asian235
American Indian or Alaska Native011
White11372185
Unknown011
Other022
08

Study locations

44 sites
  • Novartis Investigative Site
    Ciudad Autonoma de Bs As, Buenos Aires 1181, Argentina
  • Novartis Investigative Site
    Buenos Aires, C1425DKG, Argentina
  • Novartis Investigative Site
    Pleven, 5800, Bulgaria
  • Novartis Investigative Site
    Plovdiv, 4002, Bulgaria
  • Novartis Investigative Site
    Sofia, 1407, Bulgaria
  • Novartis Investigative Site
    Sofia, 1431, Bulgaria
  • Novartis Investigative Site
    Sofia, 1632, Bulgaria
  • Novartis Investigative Site
    Markham, Ontario L3P 1X2, Canada
  • Novartis Investigative Site
    Sudbury, Ontario P3C 1X8, Canada
  • Novartis Investigative Site
    Aarhus N, 8200, Denmark
  • Novartis Investigative Site
    Tallinn, 10138, Estonia
  • Novartis Investigative Site
    Tallinn, 13419, Estonia
  • Novartis Investigative Site
    Tartu, 50406, Estonia
  • Novartis Investigative Site
    Tampere, 33100, Finland
  • Novartis Investigative Site
    Turku, FIN-20100, Finland
  • Novartis Investigative Site
    Berlin, 10789, Germany
  • Novartis Investigative Site
    Berlin, 13353, Germany
  • Novartis Investigative Site
    Erlangen, 91054, Germany
  • Novartis Investigative Site
    Frankfurt, 60590, Germany
  • Novartis Investigative Site
    Nyiregyhaza, 4400, Hungary
  • Novartis Investigative Site
    Szolnok, 5000, Hungary
  • Novartis Investigative Site
    Bialystok, 15-879, Poland
  • Novartis Investigative Site
    Bydgoszcz, 85-094, Poland
  • Novartis Investigative Site
    Gdansk, 80-803, Poland
  • Novartis Investigative Site
    Krakow, 31-070, Poland
  • Novartis Investigative Site
    Lodz, 90-436, Poland
  • Novartis Investigative Site
    Lodz, 90-647, Poland
  • Novartis Investigative Site
    Badalona, Catalunya 08916, Spain
  • Novartis Investigative Site
    Barcelona, Catalunya 08003, Spain
  • Novartis Investigative Site
    Barcelona, Catalunya 08036, Spain
  • Novartis Investigative Site
    Alicante, Comunidad Valenciana 03010, Spain
  • Novartis Investigative Site
    Valencia, Comunidad Valenciana 46014, Spain
  • Novartis Investigative Site
    Alcorcon, Madrid 28922, Spain
  • Novartis Investigative Site
    Las Palmas de Gran Canaria, 35010, Spain
  • Novartis Investigative Site
    Madrid, 28006, Spain
  • Novartis Investigative Site
    Madrid, 28031, Spain
  • Novartis Investigative Site
    Madrid, 28041, Spain
  • Novartis Investigative Site
    Goteborg, 413 46, Sweden
  • Novartis Investigative Site
    Malmo, 214 28, Sweden
  • Novartis Investigative Site
    Lausanne, CH-1011, Switzerland
  • Novartis Investigative Site
    Bradford, West Yorkshire BD5 0NA, United Kingdom
  • Novartis Investigative Site
    Leeds, West Yorkshire LS7 4SA, United Kingdom
  • Novartis Investigative Site
    London, SE1 9RT, United Kingdom
  • Novartis Investigative Site
    Salford, M6 8HD, United Kingdom
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2017 to primary completion in Nov 2021, 56 months.

Results were first posted in Oct 2024, 2 years 10 months after primary completion.

Of 40 industry-sponsored phase 4 interventional studies under Psoriasis, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 29. This study's 56 months is above that.

Counting every sponsor, half of 115 studies reached it within 23 months; a quarter within 12 and three quarters within 43.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 23, 2016
First posted
Jan 13, 2017
StartActual
Mar 27, 2017
Primary completionActual
Nov 30, 2021
CompletionActual
Jun 16, 2023
Results first posted
Oct 1, 2024
Last update
Jan 28, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 28, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03020199
Responsible party
Sponsor
First posted
Jan 13, 2017
Start date
Mar 27, 2017
Primary completion
Nov 30, 2021
Completion
Jun 16, 2023
Results posted
Oct 1, 2024
Last update
Jan 28, 2025

Study contacts

Novartis Pharmaceuticals
study director · Novartis Pharmaceuticals

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Secukinumab

Start the discussion